Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 306

1.

Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements.

Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, Khan MA, Sethi G.

Biomolecules. 2019 Nov 13;9(11). pii: E735. doi: 10.3390/biom9110735. Review.

2.

Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems.

Dehshahri A, Ashrafizadeh M, Ghasemipour Afshar E, Pardakhty A, Mandegary A, Mohammadinejad R, Sethi G.

Pharmacol Res. 2019 Nov 17;151:104551. doi: 10.1016/j.phrs.2019.104551. [Epub ahead of print] Review.

PMID:
31743776
3.

Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway.

Lee JH, Chinnathambi A, Alharbi SA, Shair OHM, Sethi G, Ahn KS.

Pharmacol Res. 2019 Dec;150:104504. doi: 10.1016/j.phrs.2019.104504. Epub 2019 Oct 31.

PMID:
31678208
4.

Engineering anti-cancer nanovaccine based on antigen cross-presentation.

Warrier VU, Makandar AI, Garg M, Sethi G, Kant R, Pal JK, Yuba E, Gupta RK.

Biosci Rep. 2019 Oct 30;39(10). pii: BSR20193220. doi: 10.1042/BSR20193220.

5.

RNF6 promotes myeloma cell proliferation and survival by inducing glucocorticoid receptor polyubiquitination.

Ren Y, Xu X, Mao CY, Han KK, Xu YJ, Cao BY, Zhang ZB, Sethi G, Tang XW, Mao XL.

Acta Pharmacol Sin. 2019 Oct 23. doi: 10.1038/s41401-019-0309-6. [Epub ahead of print]

PMID:
31645658
6.

Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition.

Cheng JT, Wang L, Wang H, Tang FR, Cai WQ, Sethi G, Xin HW, Ma Z.

Cells. 2019 Sep 30;8(10). pii: E1178. doi: 10.3390/cells8101178. Review.

7.

Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma.

Lee JH, Rangappa S, Mohan CD; Basappa, Sethi G, Lin ZX, Rangappa KS, Ahn KS.

Biomolecules. 2019 Sep 30;9(10). pii: E550. doi: 10.3390/biom9100550.

8.

Nanoparticles Targeting STATs in Cancer Therapy.

Ashrafizadeh M, Ahmadi Z, Kotla NG, Afshar EG, Samarghandian S, Mandegary A, Pardakhty A, Mohammadinejad R, Sethi G.

Cells. 2019 Sep 27;8(10). pii: E1158. doi: 10.3390/cells8101158. Review.

9.

The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.

Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY.

Cells. 2019 Sep 20;8(10). pii: E1118. doi: 10.3390/cells8101118. Review.

10.

Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms.

Gupta A, Singh AK, Kumar R, Ganguly R, Rana HK, Pandey PK, Sethi G, Bishayee A, Pandey AK.

Molecules. 2019 Sep 19;24(18). pii: E3399. doi: 10.3390/molecules24183399. Review.

11.

Fangchinoline, a Bisbenzylisoquinoline Alkaloid can Modulate Cytokine-Impelled Apoptosis via the Dual Regulation of NF-κB and AP-1 Pathways.

Jung YY, Shanmugam MK, Chinnathambi A, Alharbi SA, Shair OHM, Um JY, Sethi G, Ahn KS.

Molecules. 2019 Aug 28;24(17). pii: E3127. doi: 10.3390/molecules24173127.

12.

Hydrogen Sulfide Prevents Elastin Loss and Attenuates Calcification Induced by High Glucose in Smooth Muscle Cells through Suppression of Stat3/Cathepsin S Signaling Pathway.

Zhou YB, Zhou H, Li L, Kang Y, Cao X, Wu ZY, Ding L, Sethi G, Bian JS.

Int J Mol Sci. 2019 Aug 27;20(17). pii: E4202. doi: 10.3390/ijms20174202.

13.

An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases.

Roy NK, Parama D, Banik K, Bordoloi D, Devi AK, Thakur KK, Padmavathi G, Shakibaei M, Fan L, Sethi G, Kunnumakkara AB.

Int J Mol Sci. 2019 Aug 22;20(17). pii: E4101. doi: 10.3390/ijms20174101. Review.

14.

Natural product-based nanoformulations for cancer therapy: Opportunities and challenges.

Kashyap D, Tuli HS, Yerer MB, Sharma A, Sak K, Srivastava S, Pandey A, Garg VK, Sethi G, Bishayee A.

Semin Cancer Biol. 2019 Aug 14. pii: S1044-579X(19)30103-8. doi: 10.1016/j.semcancer.2019.08.014. [Epub ahead of print] Review.

PMID:
31421264
15.

Correction: Vanillic acid attenuates testosterone-induced benign prostatic hyperplasia in rats and inhibits proliferation of prostatic epithelial cells.

Jung Y, Park J, Kim HL, Youn DH, Kang J, Lim S, Jeong MY, Sethi G, Park SJ, Ahn KS, Um JY.

Oncotarget. 2019 Jul 16;10(44):4611. doi: 10.18632/oncotarget.27105. eCollection 2019 Jul 16.

16.

A Brief Overview of the Antitumoral Actions of Leelamine.

Merarchi M, Jung YY, Fan L, Sethi G, Ahn KS.

Biomedicines. 2019 Jul 19;7(3). pii: E53. doi: 10.3390/biomedicines7030053. Review.

17.

Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.

Kim C, Lee JH, Ko JH, Chinnathambi A, Alharbi SA, Shair OHM, Sethi G, Ahn KS.

Biomolecules. 2019 Jul 7;9(7). pii: E262. doi: 10.3390/biom9070262.

18.

Anti-cancer effects of oxymatrine are mediated through multiple molecular mechanism(s) in tumor models.

Halim CE, Xinjing SL, Fan L, Bailey Vitarbo J, Arfuso F, Tan CH, Narula AS, Kumar AP, Sethi G, Ahn KS.

Pharmacol Res. 2019 Sep;147:104327. doi: 10.1016/j.phrs.2019.104327. Epub 2019 Jul 5. Review.

PMID:
31283981
19.

Functional interplay between YY1 and CARM1 promotes oral carcinogenesis.

Behera AK, Kumar M, Shanmugam MK, Bhattacharya A, Rao VJ, Bhat A, Vasudevan M, Gopinath KS, Mohiyuddin A, Chatterjee A, Sethi G, Kundu TK.

Oncotarget. 2019 Jun 4;10(38):3709-3724. doi: 10.18632/oncotarget.26984. eCollection 2019 Jun 4.

20.

Focus on Formononetin: Anticancer Potential and Molecular Targets.

Ong SKL, Shanmugam MK, Fan L, Fraser SE, Arfuso F, Ahn KS, Sethi G, Bishayee A.

Cancers (Basel). 2019 May 1;11(5). pii: E611. doi: 10.3390/cancers11050611. Review.

Supplemental Content

Loading ...
Support Center